1. HBW Insight
  2. >>Health
  3. >>Business

Perrigo’s Pending OTC Launches Promising But Pandemic Precludes Pumping Guidance

 
• By Eileen Francis

A diclofenac topical analgesic is first, likely followed by a line extension for its Prevacid 24HR PPI brand. Perrigo also plans to introduce natural-based products that “leverage our expertise in Europe."

Quarterly resluts on typewriter close up

Perrigo Company PLC expects OTC product launches from its $500m pipeline that will reach the market over the next year to start during the current quarter with a diclofenac topical analgesic, likely followed by a line extension for its Prevacid 24HR proton pump inhibitor brand.

Additionally, the Dublin-based private label and store brand OTC market leader is planning to introduce natural-based products that “leverage our...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

People On The Move: Appointments At Klosterfrau, Haleon, Opella

 
• By Tom Gallen

A round-up of the latest consumer health industry appointments: Kloserfrau makes changes to management in Germany; Haleon hires Pakistan head; Opella names Americas leader.

Stada Held Back By Weak Cough & Cold Season

 
• By Tom Gallen

While sales of seasonal products struggled during Q1, Stada pointed to the continuing strength of its underlying Consumer Healthcare portfolio.

US Consumer Health, Beauty Sectors: Expecting Tariff Policy Changes, Buckling Up For The Ride

 
• By Malcolm Spicer

As firms in OTC drug, dietary supplement and personal care/beauty sectors reported results for January-March period after Trump announced reciprocal tariffs, they buckled up for more changes in the president’s thinking likely to affect consumer spending as well as their costs.

Galenica’s Verfora Gets Off To Flying Start In Swiss CHC Market

 
• By Tom Gallen

Verfora grows almost 10-times faster than the Swiss consumer health market in the opening months of 2025.

More from Health

AESGP Annual Meeting: Commission Must ‘Think Carefully’ Before Reverse-Switching Antimicrobials

 
• By David Ridley

If the European Commission is serious about improving the competitiveness of the European Union, it should ditch the idea of making commonly used OTC antimicrobials like thrush treatments and cold sore creams prescription-only, warns Greek Medicines Agency president Evangelos Manolopoulos

Stada Held Back By Weak Cough & Cold Season

 
• By Tom Gallen

While sales of seasonal products struggled during Q1, Stada pointed to the continuing strength of its underlying Consumer Healthcare portfolio.

AESGP Annual Meeting: Wastewater Directive Impact Assessment ‘Fundamentally Flawed’

 
• By David Ridley

AESGP president Jonathan Workman opens the 61st Annual Meeting with calls for industry unity in the face of the problematic revised EU Urban Wastewater Treatment Directive.